Docstoc

Beena Consulting Expert extension of your R_D effort Afshin

Document Sample
Beena Consulting Expert extension of your R_D effort Afshin Powered By Docstoc
					Beena Consulting
Expert extension of your R&D effort
                                                                          Afshin Shafiee, Ph.D. (CEO)

         There is a new paradigm emerging in        Our mission is to provide our clients with:
the world of ophthalmic pharmaceutical
research and development (R&D), with a                     First-class, customized service
                                                           Rapid turnaround
growing number of pharmaceutical companies
utilizing outsourced R&D and in-licensing of               State of the art science
later-stage therapeutic candidates, to replace             Evidence-based final product
functions that have traditionally been served by           Cost-effective results
internal discovery and early stage preclinical      For more information and to request a quote
drug development efforts. These changes in          for any of our services, please visit us at
business strategy are projected to reduce           www.Beenaco.com.
significantly the cost of development of new
products that can be advanced to clinical trials.   Whether your company already has an existing
With more R&D support being outsourced,             commitment to eye pharmaceuticals, or is
there is a corresponding need for expert,           about to launch an ophthalmics program, we
focused scientific review, management, and          can offer several options to help you guide,
analysis associated with these projects.            optimize, and advance your preclinical R&D
                                                    effort towards your ultimate goal of human
Beena Consulting is founded by Dr. Afshin           clinical trials.
Shafiee (Ph.D.) with 15 years of experience in
the ophthalmic pharmaceutical industry and          Services:
academia,       demonstrating         specialized                 Project management
knowledge in ocular pharmacology, cell biology,
and pathophysiology. Our scientific expertise        Evaluation and selection of contract research
                                                                 organizations (CROs)
and management skills, covering a wide array of
eye disease indications, have been called upon              Assay development and validation
to lead successful preclinical teams at Bausch +                Drug target identification
Lomb consisting of both internal scientific staff
and/or scientists working in contract                 Drug testing/screening analysis: efficacy and
laboratories. These efforts have contributed to                    therapeutic index
“go/no go” decisions that made a difference
                                                       Animal model selection and development
between drugs and biologicals advancing to IND
status or not—in either case resulting in                            Due diligence
optimized investment of effort and budget
allocation.



Beena Consulting, 125 Maywood Avenue, Rochester, NY 14618, USA.
Phone: (585) 752-3961
   Fax: (206) 339-7379
Email: afshin.shafiee@beenaco.com
Website: www.beenaco.com
Beena Consulting
Expert extension of your R&D effort
                                                                       Afshin Shafiee, Ph.D. (CEO)

                                                         selection of hits and lead compounds
Examples of our proven expertise and success:            from a chemical library, advancing to
                                                         further ranking and efficacy profiling in
     Generation and refinement of clinically            secondary functional assays, as well as
relevant assays involving both in vitro and              comprehensive in vitro pharmacological
animal models of ocular indications such as              profile of single compounds, including
anterior and/or posterior segment uveitis,               simultaneous testing with standard
bacterial infections, diabetic macular edema,            clinically-accepted agents.
glaucoma (elevated IOP), and retinal and                Preclinical formulation of drugs and
choroidal neovascularization.                            biological agents for testing in cell and
                                                         organ culture, and for appropriate
In vitro assays:                                         administration in animal models, for
  Angiogenesis assays (attachment, migration,            both proof-of-concept and efficacy
 proliferation and tube formation) using primary
                                                         studies.
          ocular vascular endothelial cells

 Inflammatory cytokine profiling using primary
              cells and cell lines


In vivo assays:
    Laser-induce choroidal neovascularization

       Oxygen-induced retinopathy (OIR)

  Vascular endothelial growth factor (VEGF)-
         induced hyperpermeability

  Mitogen- or endotoxin-induced anterior or
               posterior uveitis

          Post-surgical inflammation

              IOP measurements


     Development of critical paths for drug
      discovery and development, including

Beena Consulting, 125 Maywood Avenue, Rochester, NY 14618, USA.
Phone: (585) 752-3961
   Fax: (206) 339-7379
Email: afshin.shafiee@beenaco.com
Website: www.beenaco.com

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:2
posted:11/29/2011
language:English
pages:2